"We have discovered something that could help millions of people"
The spin-out company Notify Therapeutics is in the middle of creating a genuine paradigm shift in fertility treatment. Meet the founder, Professor Karin Lykke-Hartmann from the Department of Biomedicine, in the next installment of our series on external collaboration at Health.
Since her Ph.D. days at Yale University, Karin Lykke-Hartmann has worked with reproductive biology. However, until a few years ago, she had never imagined that she would start her own company in the field.
Yet, that's exactly what happened. Two and a half years ago, the spin-out company Notify Therapeutics was born, with Karin Lykke-Hartmann as its founder and CEO.
The company is built around a completely new type of non-hormonal fertility treatment for women, which has the potential to revolutionize the field, and make it possible to help millions of infertile women who do not benefit from conventional treatment.
Watch the video where Karin Lykke-Hartmann talks about her journey into entrepreneurship.
Thinking of taking your research beyond AU?
If you're considering starting a spin-out company, a research project with a private company, or other types of external collaboration, then reach out to AU's Technology Transfer Office (TTO).
TTO can assist you with everything from collaboration contracts to patenting. Learn more on TTO's website.
Contact
Professor Karin Lykke-Hartmann
Aarhus University, Department of Biomedicine
Mobile: (+45) 29 39 05 58
Mail: kly@biomed.au.dk